Drugs and Pharmaceuticals

The Texas Contract Vehicle 269-A1 is a multi-award pharmaceutical procurement vehicle established to supply drugs and pharmaceuticals to state institutions. The vehicle encompasses a focused set of pharmaceutical products including combination antiasthma agents, ipratropium bromide, calfactant, amiphenazole, and bemegride, along with broader categories covering antihistamine drugs, central nervous system agents, expectorants, antitussives, mucolytic agents, eye/ear/nose/throat preparations, and gastrointestinal drugs. These products are specifically procured to support the healthcare and personal care needs of Texas state correctional and juvenile justice facilities, including the Texas Department of Criminal Justice Institutional Division and the Texas Juvenile Justice Department. The vehicle emphasizes institutional medical supply requirements with standardized packaging specifications, UPC labeling, and precise delivery protocols.

The Texas Contract Vehicle 269-A1 is administered by the CPA Contract Management division of the Texas Comptroller of Public Accounts and operates statewide throughout Texas under a term contract structure. The vehicle award date is August 1, 2025, with a completion date of July 31, 2027. Three prime contractors hold awards under this vehicle: Barbco, Inc. dba Rudy Love Distributing; National Food Group, Inc.; and Keefe Group, LLC. All awards maintain tax-exempt status under Texas Tax Code Section 151.309(4) and follow standardized delivery windows of 7–14 days after receipt of order, with deliveries directed to designated TDCJ commissary warehouses and institutional facilities.

The vehicle encompasses three individual IDVs, each representing a distinct prime contractor relationship. The first IDV, held by Barbco, Inc., operated from December 20, 2021, through July 31, 2025, with cumulative award values ranging from $684.00 to $21,468.70. The second IDV, held by National Food Group, Inc., also spanned the same period and demonstrated cumulative award values from approximately $136 to $22,032, with multiple awards to various vendors including Athlete's Needs, Inc. and Drugstore Products, Inc. The third IDV, held by Keefe Group, LLC, similarly operated from December 20, 2021, through July 31, 2025, with individual awards ranging from $39.60 to $15,585.60, reflecting flexible procurement quantities from 8 to 816 cases. Collectively, these three IDVs establish a robust, multi-vendor pharmaceutical supply network designed to meet the diverse and responsive medical supply requirements of Texas state institutions.